- American City Business Journals•39 minutes ago
Vertex Pharmaceuticals announced a plan late Tuesday to begin trials before the end of the year of the third in its so-called “triple combo” of pills designed to treat as much as 90 percent of the 75,000 patients worldwide who suffer from cystic fibrosis. Vertex (VRTX) said it will begin mid-stage trials of two drugs known as VX-152 and VX-440 before next year, in 35 and 40 patients respectively, with results expected in the second half of 2017. The third drug in that the company calls its “triple combo” is Kalydeco, which earned FDA approval in 2012.
- Associated Press•13 hours ago
Vertex Pharmaceuticals Inc. on Tuesday reported a loss of $41.8 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of 17 cents. Earnings, adjusted for stock ...
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||82.50 x 100|
|Ask||84.00 x 500|
|Day's Range||77.43 - 79.75|
|52wk Range||75.90 - 134.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-69.41|
|Avg Vol (3m)||1,423,026|
|Dividend & Yield||N/A (N/A)|